Real-Time Protein Folding for Therapeutics

Replace months of wet-lab experimentation with seconds of AI simulation. Our platform enables high-throughput virtual screening of protein structures against target binding sites, rapidly identifying the most promising therapeutic leads. This reduces the initial discovery phase from 12-18 months to mere weeks.

• Real-World Impact: A top-10 pharma company used this approach to screen 2.5 million compounds in 48 hours, identifying 3 novel leads for an oncology target.
• ROI Driver: Cuts early-stage R&D costs by up to 60% and de-risks pipeline investments by focusing resources on high-probability candidates.

Ensure structural fidelity and functional equivalence of biosimilars with atomic-level precision. Our AI provides instant, high-fidelity comparisons between originator and biosimilar protein structures, predicting stability and immunogenicity risks before manufacturing.

• Real-World Impact: A biosimilar developer avoided a failed $50M clinical trial by identifying a critical misfolding variant in their lead candidate during pre-clinical analysis.
• ROI Driver: Protects massive development investments and accelerates time-to-market for high-value products by streamlining regulatory evidence generation.

Design next-generation biologics with enhanced shelf-life and efficacy. Use AI to simulate thousands of protein variants in-silico, predicting how single-point mutations affect thermal stability, aggregation propensity, and expression yield.

• Real-World Impact: A biotech firm engineered a monoclonal antibody with a 15°C higher melting point, enabling simpler cold-chain logistics and expanding market access in emerging regions.
• ROI Driver: Reduces downstream manufacturing and formulation challenges, leading to higher production success rates and lower cost of goods sold (COGS).

Dramatically shorten the therapeutic response timeline for novel viral threats. Our platform allows researchers to fold and analyze unknown viral proteins in real-time, enabling rapid design of neutralizing antibodies or peptide inhibitors.

• Real-World Impact: During a recent zoonotic outbreak, a research consortium mapped the spike protein of a novel coronavirus and designed 50 candidate binders in 72 hours.
• ROI Driver: Creates a strategic capability for pandemic preparedness and positions organizations as first-movers in emerging therapeutic markets, capturing significant value.

Maximize the therapeutic index of complex ADCs by optimizing the linker-payload attachment site. AI models predict how conjugation affects the antibody's structure, stability, and binding affinity, ensuring the payload is delivered effectively.

• Real-World Impact: An ADC developer used this approach to select a conjugation site that improved tumor cell killing by 40% while reducing off-target liver toxicity.
• ROI Driver: Increases the probability of clinical success for one of the most valuable and complex therapeutic modalities, protecting R&D budgets that can exceed $1B per program.

Anticipate and solve Chemistry, Manufacturing, and Controls (CMC) challenges before they reach the pilot plant. Use folding predictions to forecast expression yields, purification behavior, and formulation stability, informing process development.

• Real-World Impact: A manufacturer avoided a major scale-up failure by identifying a propensity for aggregation under fermentation conditions, allowing for a pre-emptive process redesign.
• ROI Driver: Reduces costly tech-transfer delays and manufacturing batch failures, accelerating overall development timelines and improving asset valuation.

Traditional wet-lab methods for determining a protein's 3D structure can take months. AI-powered real-time folding delivers high-fidelity predictions in seconds, allowing your team to screen thousands of potential drug candidates virtually before committing to costly synthesis. This compresses the 'hit-to-lead' phase from quarters to weeks, enabling rapid iteration and a faster, more robust pipeline.

For biosimilars, demonstrating structural equivalence to the reference product is a critical, expensive hurdle. Real-time folding provides instant, high-confidence comparisons of your molecule's predicted structure against the target. This enables:

• Early identification of conformational mismatches that could impact efficacy or safety.
• Optimization of expression systems by predicting how changes affect folding.
• Stronger regulatory submissions backed by AI-powered structural data, reducing the risk of costly late-stage failures.

Move beyond small molecules and antibodies. AI folding is essential for designing next-generation protein-based therapeutics, including:

• Enzymes for metabolic disorders.
• Peptide therapeutics with complex folding requirements.
• Multi-specific antibodies and CAR-T cell receptors. By accurately modeling how these complex proteins fold and interact, you can pioneer new treatment avenues with higher confidence and a clearer path to clinical success.

The investment justification is clear and measurable. Real-time protein folding directly impacts the bottom line by:

• Reducing wet-lab costs: Cut spending on failed synthesis and characterization by up to 60%.
• Shortening time-to-market: Every month saved in development can translate to millions in potential revenue for a blockbuster drug.
• Increasing patent strength: Faster discovery allows you to file broader, earlier patents, securing longer market exclusivity. The ROI is not just in cost avoidance, but in accelerated revenue generation and strategic market positioning.

A mid-sized biotech used real-time folding to develop a novel enzyme replacement therapy. The AI platform:

1. Identified a folding instability in their lead candidate that traditional methods missed.
2. Suggested 3 stabilizing point mutations based on structural analysis.
3. Validated the new design in-silico in hours. The resulting molecule showed 10x greater thermal stability in subsequent lab tests, moving directly into pre-clinical studies and saving an estimated 18 months of iterative optimization.

Adoption is not a rip-and-replace. Our AI solutions integrate directly with your existing bio-informatics pipelines and lab information management systems (LIMS). Scientists access predictions through a familiar API or web interface, turning AI into a daily tool, not a disruptive project. This ensures rapid user adoption and immediate value extraction without overhauling your core IT infrastructure.